» Articles » PMID: 21750200

MiR-22 Promotes HBV-related Hepatocellular Carcinoma Development in Males

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2011 Jul 14
PMID 21750200
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Previous reports have shown that IL-1α-MyD88-IL-6 signaling is essential in promoting hepatocellular carcinoma (HCC) development in a diethylnitrosamine (DEN)-induced mouse model. We aimed to determine whether interleukin (IL)-1α regulates HCC development in humans.

Methods: HBV-associated HCC tissue, corresponding adjacent tissue, and normal tissue samples were obtained from 80 male and 36 female patients. IL-1α, ERα, IL-6, and MyD88 were quantified by using real-time PCR and Western blot. Stem-loop PCR was used to quantify miR-22 expression. Luciferase reporter assays were used to study transcriptional regulation.

Results: IL-1α was highly expressed in male tumor adjacent tissue compared with normal tissue (P = 0.025); however, this was not the case for female subjects. A linear relationship was observed between increased IL-1α and decreased ERα expression in male tumor adjacent tissue (r = -0.616, P = 0.004). Our results also indicated that estrogen (E2) was suppressed upon IL-1α secretion in ERα-overexpressed HCC cells. We detected high expression of miR-22 in male tumor adjacent tissue compared with controls (P = 0.027); furthermore, we showed that miR-22 downregulates ERα transcription by targeting the 3'-untranslated region. In the DEN-induced model, IL-1α was highly expressed in sprouting tumors and gradually decreased in conjunction with HCC development.

Conclusion: Overexpression of miR-22 in male tumor adjacent tissue was associated with downregulated ERα expression, potentially by attenuating the protective effect of estrogen and causing increased IL-1α expression. These results may explain the high incidence of HBV-associated HCC in the male population.

Citing Articles

Recent Advances in miRNA-Based Therapy for MASLD/MASH and MASH-Associated HCC.

Carpi S, Daniele S, de Almeida J, Gabbia D Int J Mol Sci. 2024; 25(22).

PMID: 39596297 PMC: 11595301. DOI: 10.3390/ijms252212229.


Advances in the study of the mechanism of action of miR‑22 in liver lesions (Review).

Wang M, Wang X, Wang Y, Gai Y, Ye J, Xu X Oncol Lett. 2024; 28(5):541.

PMID: 39310022 PMC: 11413475. DOI: 10.3892/ol.2024.14674.


Exosome microRNA-22 inhibiting proliferation, migration and invasion through regulating Twist1/CADM1 axis in osteosarcoma.

Ruan Q, Wang C, Wu Y, Zhu Q Sci Rep. 2024; 14(1):761.

PMID: 38191892 PMC: 10774347. DOI: 10.1038/s41598-023-50612-4.


Gender dimorphism in hepatocarcinogenesis-DNA methylation modification regulated X-chromosome inactivation escape molecule XIST.

Dai Z, Wang S, Guo X, Wang Y, Yin H, Tan J Clin Transl Med. 2023; 13(12):e1518.

PMID: 38148658 PMC: 10751514. DOI: 10.1002/ctm2.1518.


Gender Differences in the Pathogenesis and Risk Factors of Hepatocellular Carcinoma.

Nevola R, Tortorella G, Rosato V, Rinaldi L, Imbriani S, Perillo P Biology (Basel). 2023; 12(7).

PMID: 37508414 PMC: 10376683. DOI: 10.3390/biology12070984.